市場調査レポート

抗生物質のルネサンス:薬剤耐性バクテリアと戦う技術・市場進歩

Antibiotic Renaissance: Technology and Market Advances in the War Against Drug-Resistant Bacteria

発行 Insight Pharma Reports 商品コード 300638
出版日 ページ情報 英文 111 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.55円で換算しております。
Back to Top
抗生物質のルネサンス:薬剤耐性バクテリアと戦う技術・市場進歩 Antibiotic Renaissance: Technology and Market Advances in the War Against Drug-Resistant Bacteria
出版日: 2014年06月01日 ページ情報: 英文 111 Pages
概要

当レポートでは、研究側面、商業側面、市場側面および薬剤耐性の動向に焦点を当て、薬剤耐性バクテリアの漸進的な増加について調査しており、薬剤耐性バクテリアの歴史・状況・進歩、診断・治療研究プログラム、開発動向、および専門家へのインタビューなどを提供しています。

エグゼクティブサマリー

第1章 イントロダクション

第2章 歴史・背景

  • 抗生物質・医薬品産業
  • 診断背景

第3章 薬剤耐性の研究側面

  • 診断
    • GE Global Research/University of Washington/Epoch Biosciences
    • Massachusetts General Hospital
    • Pak Kin Wong Lab, University of Arizona
    • Q-linea AB
    • University of Tokyo/Osaka University
    • University Hospital, Basel, Switzerland
    • University of Illinois
    • University of Toronto/Xagenic
    • Brown University/MIT
    • David Greenberg Laboratory, University of Texas
    • Discuva
    • Eric Brown Lab, McMaster University
    • IBM/Institute of Bioengineering and Nanotechnology (Singapore)
    • Kenneth Keiler Laboratory, Pennsylvania State University
    • Kim Lewis Lab, Northeastern University
    • Michael Laub Laboratory, Massachusetts Institute of Technology
    • Netherlands Cancer Center/Universitat Pompeu Fabra/Hubrecht Institute
    • NovoBiotic
    • Udi Qimron Laboratory, Tel Aviv University
    • University of Illinois/University of California, San Diego
    • University of Southern Denmark
    • Washington University School of Medicine

第4章 薬剤耐性の商業側面

  • 診断製品・プロジェクト
  • 分子診断アプローチ
    • Alere
    • Atlas Genetics
    • BD Diagnostics
    • Biofire
    • Cepheid
    • Curetis
    • Diatherix
    • ELITech Molecular Diagnostics
    • Great Basin Corporation
    • Mobidiag
    • Molecular Detection Inc.
    • Q-linea AB
    • Roche Molecular Systems
    • STAT-Diagnostica
    • Culture-based Approaches
    • Accelerate Diagnostics
    • Axela Inc. and Hutman Diagnostics
    • Mass Spectrometry-based Diagnostics
    • Therapeutic Products and Projects
    • Achaogen
    • Achillion Pharmaceuticals
    • Affinium Pharmaceuticals
    • Allecra Therapeutics
    • AstraZeneca
    • Basilea Pharmaceutical
    • Biota Pharmaceuticals
    • Cellceutix
    • Cempra Pharmaceuticals
    • ContraFect
    • Cubist Pharmaceuticals
    • Durata Therapeutics
    • Enanta Pharmaceuticals
    • Forest Laboratories
    • GlaxoSmithKline
    • Helperby Therapeutics
    • Johnson & Johnson
    • Melinta Therapeutics
    • Merck
    • Nabriva Therapeutics
    • Novolytics
    • Paratek Pharmaceuticals
    • Pfizer
    • Phico Therapeutics
    • Polyphor Ltd.
    • Shionogi and Co., Ltd.
    • TaiGen Biotechnology
    • Tetraphase Pharmaceuticals
    • The Medicines Company

第5章 薬剤耐性の市場側面

  • 契約
  • 調査結果

第6章 薬剤耐性の動向

  • コンソーシアム、規制イニシアチブおよび協力プログラム
  • 感染症薬の発見者・開発者の難しさ
  • 薬物耐性を避ける薬剤の発見に対する新たなアプローチ

第7章 インタビュー記録

目次

New to Insight Pharma Reports is Antibiotic Renaissance: Technology and Market Advances in the War against Drug-resistant Bacteria. This report covers evolutionary growth of antibiotic resistant bacteria with a focus in research aspects, commercial aspects, market aspects, and trends in antibiotic resistance. Antibiotic resistance has a historical presence in the big pharma industry (documentation of its understanding leads back to 1940); however it has only recently been on the incline of popular adoption. Because of the rapid development of antibiotics and the growing pharma industry, most professionals felt secure in the belief that for every antibiotic fallen by the wayside, new ones would emerge to replace them, much to the chagrin of the smaller population of physicians and medical scientists. Due to technical difficulty, regulatory complexity, and relatively poor returns on investment, commercial drug developers became progressively less enamored with nurturing the antibiotic industry. One by one, big pharmas dropped out of the bacterial infectious disease space in favor of therapeutic areas offering greater blockbuster potential.

Although researchers have reached a point to develop antibiotics to drug-resistant bacteria, the morbidity and mortality from drug-resistant infections have resultantly scourged a variety of regions and industries, including our most useful medical facilities. In an effort to raise awareness and take action, governments, professional societies, and a growing body of medical researchers have published papers and reports that highlight the problems, call for remedial action, and propose action plans. Accordingly, academic, governmental, and commercial players have begun to ramp up activities in response to these calls to arms.

Highlighted in this report are the following concepts:

  • History, status, and progress of drug resistant bacteria
  • Evolution of today's antibiotic resistant bacteria
  • Diagnostic and therapeutic research programs directed at alleviating medical problems caused by antibiotic resistant bacteria
  • Survey results exploiting commercial diagnostic and therapeutic programs and market-related aspects of antibiotic resistance
  • Trends developing in the field
  • Exclusive interviews with six individuals who are highly knowledgeable in the subject area

Table of Contents

Executive Summary

  • Research Aspects of Antibiotic Resistance
  • Commercial Aspects of Antibiotic Resistance
  • Market Aspects
  • Trends in Antibiotic Resistance

CHAPTER 1: Introduction

  • Scope and Contents

CHAPTER 2: History and Background

  • Antibiotics and the Pharmaceutical Industry
  • Diagnostics Background

CHAPTER 3: Research Aspects of Antibiotic Resistance

  • Diagnostics
  • GE Global Research/University of Washington/Epoch Biosciences
  • Massachusetts General Hospital
  • Pak Kin Wong Lab, University of Arizona
  • Q-linea AB
  • University of Tokyo/Osaka University
  • University Hospital, Basel, Switzerland
  • University of Illinois
  • University of Toronto/Xagenic
  • Brown University/MIT
  • David Greenberg Laboratory, University of Texas
  • Discuva
  • Eric Brown Lab, McMaster University
  • IBM/Institute of Bioengineering and Nanotechnology (Singapore)
  • Kenneth Keiler Laboratory, Pennsylvania State University
  • Kim Lewis Lab, Northeastern University
  • Michael Laub Laboratory, Massachusetts Institute of Technology
  • Netherlands Cancer Center/Universitat Pompeu Fabra/Hubrecht Institute
  • NovoBiotic
  • Udi Qimron Laboratory, Tel Aviv University
  • University of Illinois/University of California, San Diego
  • University of Southern Denmark
  • Washington University School of Medicine

CHAPTER 4: Commercial Aspects of Antibiotic Resistance

  • Diagnostic Products and Projects
  • Molecular Diagnostic Approaches
  • Alere
  • Atlas Genetics
  • BD Diagnostics
  • Biofire
  • Cepheid
  • Curetis
  • Diatherix
  • ELITech Molecular Diagnostics
  • Great Basin Corporation
  • Mobidiag
  • Molecular Detection Inc.
  • Q-linea AB
  • Roche Molecular Systems
  • STAT-Diagnostica
  • Culture-based Approaches
  • Accelerate Diagnostics
  • Axela Inc. and Hutman Diagnostics
  • Mass Spectrometry-based Diagnostics
  • Therapeutic Products and Projects
  • Achaogen
  • Achillion Pharmaceuticals
  • Affinium Pharmaceuticals
  • Allecra Therapeutics
  • AstraZeneca
  • Basilea Pharmaceutical
  • Biota Pharmaceuticals
  • Cellceutix
  • Cempra Pharmaceuticals
  • ContraFect
  • Cubist Pharmaceuticals
  • Durata Therapeutics
  • Enanta Pharmaceuticals
  • Forest Laboratories
  • GlaxoSmithKline
  • Helperby Therapeutics
  • Johnson & Johnson
  • Melinta Therapeutics
  • Merck
  • Nabriva Therapeutics
  • Novolytics
  • Paratek Pharmaceuticals
  • Pfizer
  • Phico Therapeutics
  • Polyphor Ltd.
  • Shionogi and Co., Ltd.
  • TaiGen Biotechnology
  • Tetraphase Pharmaceuticals
  • The Medicines Company

CHAPTER 5: Market Aspects of Antibiotic Resistance

  • Deals
  • Survey Results

CHAPTER 6: Trends in Antibiotic Resistance

  • Consortia, Regulatory Initiatives, and Collaborative Programs
  • Difficulties for Infectious Disease Drug Discoverers and Developers
  • New Approaches to Discovering Drugs to Avoid Antibiotic Resistance

CHAPTER 7: Interview Transcripts

  • Glenn Tillotson, PhD, Senior Partner, Transcrip Partners, USA
  • David Shlaes, MD, PhD
  • Kim Lewis, Ph.D.
  • Lawrence Mehren
  • Stuart B. Levy, M.D.
  • Shana Kelley, Ph.D.
  • About Cambridge Healthtech Institute
Back to Top